atorvastatin has been researched along with Parkinsonian Disorders in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, H; Huang, J; Lai, X; Liu, A; Ma, H; Shen, M; Sun, W; Wu, J; Xu, Y; Yan, J; Yang, J | 1 |
| Castro, AA; Lapa, FR; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Viola, GG; Wiemes, BP | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| García-Estévez, DA; Navarro, C; San Millán, B; Sogo, T | 1 |
4 other study(ies) available for atorvastatin and Parkinsonian Disorders
| Article | Year |
|---|---|
Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Atorvastatin; Autophagy; Behavior, Animal; Depression; Gene Knockdown Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Movement; NADPH Oxidase 2; Neurotoxins; Oxidative Stress; Parkinsonian Disorders | 2020 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Atorvastatin; Brain; Cognition Disorders; Cytokines; Disease Models, Animal; Food Preferences; Heptanoic Acids; Male; Maze Learning; Mood Disorders; Motor Activity; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Social Behavior; Sucrose; Sweetening Agents; Swimming; Tyrosine 3-Monooxygenase | 2013 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
[Myopathy due to deficiency of desaminase myoadenilate induced by atorvastatine].
Topics: Aged; Amino Acid Substitution; AMP Deaminase; Atorvastatin; Biopsy; Causality; Creatine Kinase, MM Form; Exercise Tolerance; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Mitochondria, Muscle; Models, Genetic; Muscle, Skeletal; Mutation, Missense; Myalgia; Organic Anion Transporters; Parkinsonian Disorders; Point Mutation; Polymorphism, Single Nucleotide; Purine-Pyrimidine Metabolism, Inborn Errors; Pyrroles; Ubiquinone | 2013 |